EP08.02-073 Clinical and Genomic Analysis of Primary and Secondary MET Fusions with Intact Kinase Domain in Lung Cancer

Abstract

Several kinase gene fusions, including MET, have been uncovered as oncogenic alterations in lung cancer beyond the well-studied ALK, RET, and ROS1 fusions. As amplification and exon 14 skipping were the two most frequent MET alterations, MET fusions are rarely reported and less investigated. Though the potential role of MET fusions as a resistance mechanism to tyrosine kinase inhibitors (TKIs) has been proposed in a series of case reports, comprehensive studies remain to be performed in large cohorts.